The risk of fracture and prevalence of osteoporosis is elevated in patients with idiopathic inflammatory myopathies: cross-sectional study from a single Hungarian center.
Absorptiometry, Photon
Aged
Arthritis, Rheumatoid
/ complications
Bone Density
Cross-Sectional Studies
Female
Humans
Hungary
Male
Middle Aged
Myositis
/ complications
Osteoporosis
/ complications
Osteoporotic Fractures
/ complications
Prevalence
Quality of Life
Regression Analysis
Risk Assessment
Risk Factors
Fracture risk
Myositis
Rheumatoid arthritis
Vertebral fractures
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
02 Jul 2020
02 Jul 2020
Historique:
received:
01
11
2019
accepted:
23
06
2020
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
2
4
2021
Statut:
epublish
Résumé
The prevalence of osteoporosis and risk of fractures is elevated in rheumatoid arthritis (RA), but we have limited information about the bone mineral density (BMD) and fracture risk in patients with inflammatory myopathies. We intended to ascertain and compare fracture risk, bone mineral density and the prevalence of vertebral fractures in patients with inflammatory myositis and rheumatoid arthritis and to assess the effect of prevalent fractures on the quality of life and functional capacity. Fifty-two patients with myositis and 43 patients with rheumatoid arthritis were included in the study. Fracture Risk was determined using FRAX® Calculation Tool developed by the University of Sheffield. Dual energy X-ray absorptiometry and bidirectional thoracolumbar radiographs were performed to assess BMD and vertebral fractures. Quality of life was measured with Short Form-36 (SF-36) and physical function assessment was performed using Health Assessment Questionnaire (HAQ). We found a significantly elevated fracture risk in RA as compared to myositis patients if the risk assessment was performed without the inclusion of the BMD results. If BMD results and glucocorticoid dose adjustment were taken into account, the differences in fracture risk were no longer significant. The prevalence of osteoporosis was found to be significantly higher in the myositis group (7% vs. 13.5%, p: 0.045), but the fracture prevalence was similar in the two groups (75% vs. 68%). The fracture rates were independently associated with age in the myositis group, and with lower BMD results in the RA patients. The number of prevalent fractures was significantly correlated to poorer physical function in both groups, and poorer health status in the myositis group, but not in the RA group. Our findings suggest that inflammatory myopathies carry significantly elevated risks for osteoporosis and fractures. These higher risks are comparable to ones detected with RA in studies and strongly affect the physical function and quality of life of patients. Therefore further efforts are required to make the fracture risk assessment reliable and to facilitate the use of early preventive treatments.
Sections du résumé
BACKGROUND
BACKGROUND
The prevalence of osteoporosis and risk of fractures is elevated in rheumatoid arthritis (RA), but we have limited information about the bone mineral density (BMD) and fracture risk in patients with inflammatory myopathies. We intended to ascertain and compare fracture risk, bone mineral density and the prevalence of vertebral fractures in patients with inflammatory myositis and rheumatoid arthritis and to assess the effect of prevalent fractures on the quality of life and functional capacity.
METHODS
METHODS
Fifty-two patients with myositis and 43 patients with rheumatoid arthritis were included in the study. Fracture Risk was determined using FRAX® Calculation Tool developed by the University of Sheffield. Dual energy X-ray absorptiometry and bidirectional thoracolumbar radiographs were performed to assess BMD and vertebral fractures. Quality of life was measured with Short Form-36 (SF-36) and physical function assessment was performed using Health Assessment Questionnaire (HAQ).
RESULTS
RESULTS
We found a significantly elevated fracture risk in RA as compared to myositis patients if the risk assessment was performed without the inclusion of the BMD results. If BMD results and glucocorticoid dose adjustment were taken into account, the differences in fracture risk were no longer significant. The prevalence of osteoporosis was found to be significantly higher in the myositis group (7% vs. 13.5%, p: 0.045), but the fracture prevalence was similar in the two groups (75% vs. 68%). The fracture rates were independently associated with age in the myositis group, and with lower BMD results in the RA patients. The number of prevalent fractures was significantly correlated to poorer physical function in both groups, and poorer health status in the myositis group, but not in the RA group.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that inflammatory myopathies carry significantly elevated risks for osteoporosis and fractures. These higher risks are comparable to ones detected with RA in studies and strongly affect the physical function and quality of life of patients. Therefore further efforts are required to make the fracture risk assessment reliable and to facilitate the use of early preventive treatments.
Identifiants
pubmed: 32616032
doi: 10.1186/s12891-020-03448-2
pii: 10.1186/s12891-020-03448-2
pmc: PMC7333418
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
426Subventions
Organisme : Emberi Eroforrások Minisztériuma
ID : ÚNKP-17-2
Références
Scand J Rheumatol. 2008 Jan-Feb;37(1):40-7
pubmed: 18189194
Osteoporos Int. 2002 Oct;13(10):777-87
pubmed: 12378366
Rheumatol Int. 2012 Jun;32(6):1549-53
pubmed: 21327426
Osteoporos Int. 2011 Mar;22(3):809-16
pubmed: 21229233
J Bone Miner Res. 1994 Aug;9(8):1137-41
pubmed: 7976495
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
Scand J Rheumatol. 2008 Jul-Aug;37(4):248-54
pubmed: 18612924
Osteoporos Int. 2008 Apr;19(4):385-97
pubmed: 18292978
J Bone Miner Res. 2013 Nov;28(11):2317-24
pubmed: 23616397
Int J Rheum Dis. 2018 Mar;21(3):725-731
pubmed: 29314651
Endocrine. 2016 Apr;52(1):86-92
pubmed: 26429781
Rheumatol Int. 2013 Mar;33(3):587-92
pubmed: 22476243
Arthritis Res. 2001;3(4):221-7
pubmed: 11438040
Joint Bone Spine. 2009 May;76(3):241-7
pubmed: 19196531
J Bone Miner Res. 2015 Sep;30(9):1667-75
pubmed: 25801315
Arthritis Rheum. 2007 Mar;56(3):977-83
pubmed: 17328075
Calcif Tissue Int. 1983 May;35(3):265-7
pubmed: 6409385
Arq Bras Endocrinol Metabol. 2010 Mar;54(2):123-32
pubmed: 20485900
Ann Rheum Dis. 2010 Sep;69(9):1580-8
pubmed: 20699241
Control Clin Trials. 1991 Aug;12(4 Suppl):106S-117S
pubmed: 1663848
Bone. 2013 Sep;56(1):23-9
pubmed: 23684802
Am J Med. 1993 Jun;94(6):646-50
pubmed: 8506892